About Exelixis (NASDAQ:EXEL)
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.21%
Quick Ratio4.15%
Price-To-Earnings
Trailing P/E Ratio40.92
Forward P/E Ratio35.98
P/E GrowthN/A
Sales & Book Value
Annual Sales$452.48 million
Price / Sales13.68
Cash Flow$0.5471 per share
Price / Cash38.15
Book Value$0.96 per share
Price / Book21.74
Profitability
EPS (Most Recent Fiscal Year)$0.51
Net Income$154.22 million
Net Margins34.08%
Return on Equity81.05%
Return on Assets27.10%
Miscellaneous
Employees372
Outstanding Shares296,660,000
Exelixis (NASDAQ:EXEL) Frequently Asked Questions
What is Exelixis' stock symbol?
Exelixis trades on the NASDAQ under the ticker symbol "EXEL."
How were Exelixis' earnings last quarter?
Exelixis (NASDAQ:EXEL) announced its earnings results on Monday, February, 26th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.12. The biotechnology company earned $120.10 million during the quarter, compared to analysts' expectations of $120.25 million. Exelixis had a net margin of 34.08% and a return on equity of 81.05%. Exelixis's quarterly revenue was up 54.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.12 earnings per share. View Exelixis' Earnings History.
When is Exelixis' next earnings date?
What price target have analysts set for EXEL?
12 brokerages have issued 12-month price objectives for Exelixis' stock. Their forecasts range from $28.00 to $40.00. On average, they expect Exelixis' share price to reach $34.00 in the next twelve months. View Analyst Ratings for Exelixis.
What are Wall Street analysts saying about Exelixis stock?
Here are some recent quotes from research analysts about Exelixis stock:
- 1. Cann analysts commented, "We have not modeled any impact from international sales in the front line RCC setting; therefore, if approved by the EMA, this could provide upside to our Cabometyx outlook. Additionally, we anticipate that under the terms of the Ipsen collaboration, Exelixis will receive a milestone payment in Q1 2018 that will exceed our estimate by approximately $30 million, but the full-year 2018 will remain unchanged, resulting from the timing of this opinion being earlier in 2018 than we had anticipated." (3/20/2018)
- 2. According to Zacks Investment Research, "Exelixis put up a strong performance in 2017 driven by gain in market share for Cabometyx. Sales are expected to get a further boost as the company will launch the drug for first-line RCC which will increases the eligible patient population for Caobometyx in the United States. A potential label expansion for advanced HCC will further boost the growth prospects. Shares of the company have outperformed the industry in the past one year. However, Exelixis is heavily dependent on Cabometyx for growth. Competition should stiffen up in 2018 as the FDA accepted Bristol-Myers’ supplemental Biologics License Application for priority review of Opdivo plus Yervoy to treat intermediate- and poor-risk patients with advanced RCC with an action date in Apr 2018. Moreover, there has been a slowdown in demand of Cabometyx in recent times and hence the company might find it tough to gain further market share." (3/19/2018)
Are investors shorting Exelixis?
Exelixis saw a decrease in short interest in March. As of March 15th, there was short interest totalling 12,605,994 shares, a decrease of 10.2% from the February 28th total of 14,036,854 shares. Based on an average trading volume of 3,051,228 shares, the short-interest ratio is presently 4.1 days. Currently, 4.4% of the shares of the stock are sold short.
Who are some of Exelixis' key competitors?
Some companies that are related to Exelixis include ICON (ICLR), EXACT Sciences (EXAS), PRA Health Sciences (PRAH), Charles River Laboratories (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA), Senomyx (SNMX) and Cleveland BioLabs (CBLI).
Who are Exelixis' key executives?
Exelixis' management team includes the folowing people:
- Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 70)
- Dr. Michael M. Morrissey, CEO, Pres & Director (Age 57)
- Mr. Christopher J. Senner, Exec. VP, CFO & Principal Accounting Officer (Age 50)
- Dr. Peter Lamb Ph.D., Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 57)
- Mr. Jeffrey J. Hessekiel J.D., Exec. VP, Gen. Counsel & Sec. (Age 49)
Has Exelixis been receiving favorable news coverage?
News headlines about EXEL stock have trended somewhat positive on Monday, Accern reports. The research group ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Exelixis earned a media sentiment score of 0.07 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.22 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Exelixis?
Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Exelixis' stock price today?
One share of EXEL stock can currently be purchased for approximately $20.87.
How big of a company is Exelixis?
Exelixis has a market capitalization of $6.19 billion and generates $452.48 million in revenue each year. The biotechnology company earns $154.22 million in net income (profit) each year or $0.51 on an earnings per share basis. Exelixis employs 372 workers across the globe.
How can I contact Exelixis?
Exelixis' mailing address is 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]
MarketBeat Community Rating for Exelixis (EXEL)
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Exelixis (NASDAQ:EXEL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Exelixis in the last 12 months. Their average twelve-month price target is $34.00, suggesting that the stock has a possible upside of 62.91%. The high price target for EXEL is $40.00 and the low price target for EXEL is $28.00. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $34.00 | $34.00 | $31.7143 | $31.2857 |
| Price Target Upside: | 62.91% upside | 38.72% upside | 16.81% upside | 7.81% upside |
Exelixis (NASDAQ:EXEL) Consensus Price Target History
Exelixis (NASDAQ:EXEL) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Exelixis (NASDAQ:EXEL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Exelixis (NASDAQ EXEL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 80.28%
Exelixis (NASDAQ EXEL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Alan M Garber | Director | Sell | 15,000 | $20.25 | $303,750.00 | 76,329 |  |
| 4/11/2018 | Michael Morrissey | Insider | Sell | 90,000 | $20.78 | $1,870,200.00 | | |
| 3/6/2018 | Vincent T. Marchesi | Director | Sell | 15,000 | $24.73 | $370,950.00 | | |
| 3/2/2018 | Lance Willsey | Director | Sell | 30,000 | $23.91 | $717,300.00 | 483,273 | |
| 2/28/2018 | George Poste | Director | Sell | 15,000 | $26.26 | $393,900.00 | | |
| 2/28/2018 | Patrick J. Haley | VP | Sell | 45,029 | $27.13 | $1,221,636.77 | | |
| 1/9/2018 | Alan M Garber | Director | Sell | 15,000 | $30.30 | $454,500.00 | 64,829 | |
| 9/28/2017 | Gisela Schwab | Insider | Sell | 100,000 | $23.79 | $2,379,000.00 | | |
| 9/28/2017 | Jeffrey Hessekiel | EVP | Sell | 27,302 | $24.28 | $662,892.56 | | |
| 9/22/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $25.40 | $254,000.00 | | |
| 9/19/2017 | Stelios Papadopoulos | Director | Sell | 200,000 | $27.68 | $5,536,000.00 | | |
| 9/18/2017 | Stelios Papadopoulos | Director | Sell | 72,210 | $27.76 | $2,004,549.60 | | |
| 9/14/2017 | Michael Morrissey | Insider | Sell | 300,000 | $26.90 | $8,070,000.00 | | |
| 9/14/2017 | Patrick J. Haley | VP | Sell | 60,640 | $27.21 | $1,650,014.40 | | |
| 9/13/2017 | Lance Willsey | Director | Sell | 100,000 | $26.88 | $2,688,000.00 | 518,273 | |
| 9/12/2017 | Christopher J. Senner | CFO | Sell | 100,000 | $26.79 | $2,679,000.00 | | |
| 5/30/2017 | Patrick J. Haley | Insider | Sell | 5,000 | $18.46 | $92,300.00 | | |
| 5/15/2017 | Carl B Feldbaum | Director | Sell | 32,988 | $21.58 | $711,881.04 | 52,721 | |
| 5/10/2017 | Michael Morrissey | Insider | Sell | 211,300 | $21.87 | $4,621,131.00 | | |
| 5/9/2017 | Michael Morrissey | CEO | Sell | 100,000 | $21.69 | $2,169,000.00 | | |
| 5/8/2017 | Michael Morrissey | CEO | Sell | 11,300 | $21.81 | $246,453.00 | | |
| 5/5/2017 | Michael Morrissey | Insider | Sell | 259,149 | $22.24 | $5,763,473.76 | | |
| 5/1/2017 | Gisela Schwab | CMO | Sell | 89,910 | $23.01 | $2,068,829.10 | | |
| 4/3/2017 | Vincent T Marchesi | Director | Sell | 10,000 | $21.30 | $213,000.00 | 130,070 | |
| 3/31/2017 | Jack L Wyszomierski | Director | Sell | 5,150 | $21.57 | $111,085.50 | 78,110 | |
| 3/27/2017 | Jeffrey Hessekiel | EVP | Sell | 6,884 | $21.02 | $144,701.68 | | |
| 3/22/2017 | Jeffrey Hessekiel | EVP | Sell | 23,787 | $20.54 | $488,584.98 | | |
| 3/20/2017 | Stelios Papadopoulos | Director | Sell | 10,000 | $21.66 | $216,600.00 | 1,238,471 | |
| 3/13/2017 | Charles Cohen | Director | Sell | 10,000 | $21.82 | $218,200.00 | 238,180 | |
| 3/10/2017 | Vincent T Marchesi | Director | Sell | 40,000 | $21.98 | $879,200.00 | 160,070 | |
| 3/6/2017 | Michael Morrissey | Insider | Sell | 200,000 | $22.72 | $4,544,000.00 | | |
| 3/3/2017 | Christopher J. Senner | CFO | Sell | 11,000 | $22.80 | $250,800.00 | | |
| 3/2/2017 | George Poste | Director | Sell | 76,250 | $22.53 | $1,717,912.50 | 86,405 | |
| 1/3/2017 | Peter Lamb | EVP | Sell | 70,000 | $14.65 | $1,025,500.00 | | |
| 12/16/2016 | Carl B. Feldbaum | Director | Sell | 25,000 | $17.03 | $425,750.00 | | |
| 12/9/2016 | Alan M. Garber | Director | Sell | 7,832 | $16.90 | $132,360.80 | | |
| 12/7/2016 | George A. Scangos | Director | Sell | 204,894 | $17.81 | $3,649,162.14 | | |
| 12/5/2016 | George A. Scangos | Director | Sell | 204,718 | $17.81 | $3,646,027.58 | | |
| 12/1/2016 | Gisela Schwab | Insider | Sell | 22,000 | $16.73 | $368,060.00 | | |
| 12/1/2016 | Peter Lamb | EVP | Sell | 70,000 | $16.66 | $1,166,200.00 | | |
| 8/4/2016 | Gisela Schwab | Insider | Sell | 42,338 | $11.00 | $465,718.00 | 174,354 | |
| 5/11/2016 | Lance Willsey | Director | Buy | 60,000 | $4.97 | $298,200.00 | 548,273 | |
| 5/9/2016 | Lance Willsey | Director | Buy | 40,000 | $4.97 | $198,800.00 | 548,273 | |
| 12/11/2015 | Lance Willsey | Director | Buy | 100,000 | $4.89 | $489,000.00 | 494,975 | |
| 10/16/2015 | Peter Lamb | EVP | Sell | 51,549 | $5.80 | $298,984.20 | 36,473 | |
| 10/13/2015 | Peter Lamb | EVP | Sell | 600 | $5.80 | $3,480.00 | 36,473 | |
| 10/12/2015 | Peter Lamb | EVP | Sell | 300,276 | $5.84 | $1,753,611.84 | 36,473 | |
| 9/17/2014 | Vincent T Marchesi | Director | Buy | 20,000 | $1.71 | $34,200.00 | | |
| 8/29/2013 | Lance Willsey | Director | Buy | 10,000 | $5.15 | $51,500.00 | 333,700 | |
| 12/20/2012 | Vincent T Marchesi | Director | Buy | 4,000 | $4.68 | $18,720.00 | | |
| 12/19/2012 | Vincent T Marchesi | Director | Buy | 6,000 | $4.72 | $28,320.00 | | |
| 12/10/2012 | Gisela Schwab | EVP | Buy | 25,000 | $4.39 | $109,750.00 | | |
(Data available from 1/1/2013 forward)
Exelixis (NASDAQ EXEL) News Headlines
| Source: |
|
Exelixis (NASDAQ:EXEL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Exelixis (NASDAQ:EXEL) Income Statement, Balance Sheet and Cash Flow Statement
Exelixis (NASDAQ EXEL) Stock Chart for Monday, April, 23, 2018
Loading chart…
